Template:Short description Template:Use dmy dates Template:Cs1 config Template:Infobox medical condition (new)
Thalassemias are a group of inherited blood disorders that manifest as the production of reduced hemoglobin.<ref name="NIH2012What">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> Symptoms depend on the type of thalassemia and can vary from none to severe, including death.<ref name="NHLBI-Symptoms">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> Often there is mild to severe anemia (low red blood cells or hemoglobin) as thalassemia can affect the production of red blood cells and also affect how long the red blood cells live.<ref name="NHLBI-Symptoms" /> Symptoms include tiredness, pallor, bone problems, an enlarged spleen, jaundice, pulmonary hypertension, and dark urine.<ref name="NHLBI-Symptoms"/> Children's' growth and development may be slower than normal.<ref name="NHLBI-Symptoms"/>
Thalassemias are genetic disorders.<ref name="NHLBI-Cause">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> Alpha thalassemia is caused by deficient production of the alpha globin component of hemoglobin, while beta thalassemia is a deficiency in the beta globin component.<ref name="NIH2012What" /> The severity of alpha and beta thalassemia depends on how many of the four genes for alpha globin or two genes for beta globin are faulty.<ref name="NHLBI-Cause" /> Diagnosis is typically by blood tests including a complete blood count, special hemoglobin tests, and genetic tests.<ref name="NHLBI-Diagnosis">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> Diagnosis may occur before birth through prenatal testing.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>
Treatment depends on the type and severity.<ref name="NIH2012Tx">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> Clinically, thalassemia is classed as Transfusion-Dependent Thalassemia (TDT) or non-Transfusion-Dependent Thalassemia (NTDT), since this determines the principal treatment options. TDT requires regular blood transfusions, typically every two to five weeks. TDTs include beta-thalassemia major, hemoglobin H disease, and severe HbE/beta-thalassemia. NTDT does not need regular transfusions but may require transfusion in case of an anemia crisis.<ref>Template:Cite journal</ref> Complications of transfusion include iron overload with resulting heart or liver disease.<ref name="NHLBI-Symptoms" /> Other symptoms of thalassemias include enlargement of the spleen, frequent infections, and osteoporosis.<ref name="NHLBI-Symptoms" />
The Template:As of Global Burden of Disease Survey found that 1.31 million people worldwide have severe thalassemia while thalassemia trait occurs in 358 million people, causing 11,100 deaths per annum. It is slightly more prevalent in males than females.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> It is most common among people of Greek, Italian, Middle Eastern, South Asian, and African descent.<ref name="NIH2012What" /> Those who have minor degrees of thalassemia, in common with those who have sickle-cell trait, have some protection against malaria, explaining why sickle-cell trait and thalassemia are historically more common in regions of the world where the risk of malaria is higher.<ref>Template:Cite book</ref>Template:TOC limit
Etymology and synonymEdit
The word thalassemia (Template:IPAc-en) derives from the Greek thalassa (θάλασσα), "sea",<ref>Template:LSJ.</ref> and Neo-Latin -emia (from the Greek compound stem -aimia (-αιμία), from haima (αἷμα), "blood").<ref>Template:LSJ.</ref> It was coined because the condition called "Mediterranean anemia" was first described in people of Mediterranean ethnicities. "Mediterranean anemia" was renamed thalassemia major once the genetics were better understood. The word thalassemia was first used in 1932.<ref name="Greer2013_13">Template:Cite book</ref>Template:Rp<ref>Template:Cite journal</ref>
Hemoglobin structural biologyEdit
Normal human hemoglobins are tetrameric proteins composed of two pairs of globin chains, each of which contains one alpha-like (α-like) chain and one beta-like (β-like) chain. Each globin chain is associated with an iron-containing heme molecular component. Throughout life, the synthesis of the alpha-like and the beta-like chains is balanced so that their ratio is relatively constant and there is no excess of either type.<ref>Weatherall DJ. The New Genetics and Clinical Practice, Oxford University Press, Oxford 1991.</ref>
The specific alpha and beta-like chains that are incorporated into hemoglobins are highly regulated during development:<ref name="BWH-2002" />
- Embryonic hemoglobins are expressed as early as four to six weeks of embryogenesis and disappear around the eighth week of gestation as they are replaced by fetal hemoglobin.<ref>Huisman TH. The structure and function of normal and abnormal haemoglobins. In: Baillière's Clinical Haematology, Higgs DR, Weatherall DJ (Eds), W.B. Saunders, London 1993. p.1.</ref><ref>Natarajan K, Townes TM, Kutlar A. Disorders of hemoglobin structure: sickle cell anemia and related abnormalities. In: Williams Hematology, 8th ed, Kaushansky K, Lichtman MA, Beutler E, et al. (Eds), McGraw-Hill, 2010. p.ch.48.</ref>
- Fetal hemoglobin (HbF) is produced from approximately eight weeks of gestation through to birth and constitutes approximately 80 percent of hemoglobin in the full-term neonate. It declines during the first few months of life and constitutes <1 percent of total hemoglobin by and past early childhood. HbF is composed of two alpha globins and two gamma globins (α2γ2).<ref name="BWH-2002" />
- Adult hemoglobin (HbA) is produced at low levels through embryonic and fetal life and is the predominant hemoglobin in children by six months of age and onward; it constitutes 96-97% of total hemoglobin in individuals without a hemoglobinopathy. It is composed of two alpha globins and two beta globins (α2β2).<ref name="BWH-2002">{{#invoke:citation/CS1|citation
|CitationClass=web }}</ref>
- Hemoglobin A2 (HbA2) is a minor adult hemoglobin that normally accounts for approximately 2.5-3.5% of total hemoglobin. It is composed of two alpha globins and two delta globins (α2δ2).<ref name="BWH-2002" />
SymptomsEdit
Symptoms depend on the type and severity of thalassemia. Carriers of thalassemia genes may have no symptoms (thalassemia minor) or very mild symptoms with occasional crisis (thalassemia intermedia); individuals who are homozygous for the mutation have severe and life threatening symptoms (thalassemia major).<ref name="Mayo-2021">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>
Alpha thalassemia major is generally fatal to the unborn child, as the absence of alpha globin means that zero functional hemoglobin is produced during gestation. Unmatched gamma globin chains cluster to form hemoglobin Bart's, which is ineffective at transporting oxygen. In this situation, a fetus will develop hydrops fetalis, a form of edema, which can be detected on prenatal ultrasound.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> The child will normally die before or shortly after birth, unless intrauterine blood transfusion is performed.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> Less severe alpha thalassemia may affect growth and development.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>
Beta thalassemia symptoms typically begin to show during the first six months of life, as the body winds down production of fetal hemoglobin HbF. In a normal individual, this would be replaced by adult hemoglobin HbA.<ref name="Mayo-2021" />
If thalassemia is untreated or undetected in the infant, this can lead to developmental issues such as slowed growth, delayed puberty, bone abnormalities, and intellectual impairment.<ref name="Hanna_2022">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>
More generally, impaired production of hemoglobin causes anemia, resulting in tiredness and a general lack of energy, shortness of breath, rapid or irregular heartbeat, dizziness, pale skin, yellowing of the skin and eyes (jaundice).<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>
In thalassemia, ineffective erythropoiesis causes the bone marrow to expand. This expansion is a compensatory response to the damage caused to red blood cells by the imbalanced production of globin chains.<ref>Template:Cite journal</ref> Bone marrow expansion can lead to abnormal bone structure, particularly in the skull and face. Expansion of the bone marrow in the developing child leads to a distinctive facial shape often referred to as "Chipmunk facies".<ref>Template:Cite journal</ref> Other skeletal changes include osteoporosis,<ref name="Hanna_2022" /> growth retardation, and malformation of the spine.<ref name="Mayo-2021" /><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>
People with thalassemia can get too much iron in their bodies, either from the disease itself as RBCs are destroyed, or as a consequence of frequent blood transfusions. Excess iron is not excreted, but forms toxic non-transferrin-bound iron.<ref name="Mayo-2021" /><ref>Template:Cite journal</ref> This can lead to organ damage, potentially affecting the heart, liver, endocrine system, bones and spleen. Symptoms include an irregular heartbeat, cardiomyopathy, cirrhosis of the liver, hypothyroidism, delayed puberty and fertility problems, brittle and deformed bones, and an enlarged spleen.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>
The spleen is the organ which removes damaged red blood cells from circulation; in thalassemia patients it is abnormally active, causing it to enlarge and possibly become hyperactive, a condition called hypersplenism.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>
The immune system can become compromised in a number of ways; anemia, iron overload, and hypersplenism may affect the immune response and increase the risk of severe infection.<ref name="Mayo-2021" /><ref>Template:Cite journal</ref>
PathophysiologyEdit
<section begin="Pathophys" /> Hemoglobin is a protein containing iron that facilitates the transportation of oxygen in red blood cells.<ref>Template:Cite book</ref> Hemoglobin in the blood carries oxygen from the lungs to the other tissues of the body, where it releases the oxygen to enable metabolism. A healthy level of hemoglobin for men is between 13.2 and 16.6 grams per deciliter, and in women between 11.6 and 15 g/dl.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>
Normal adult hemoglobin (HbA) is composed of four protein chains, two α and two β-globin chains arranged into a heterotetramer. In thalassemia, patients have defects in the noncoding region of either the α or β-globin genes, causing ineffective production of normal alpha- or beta-globin chains, which can lead to ineffective erythropoiesis, premature red blood cell destruction, and anemia.<ref name="Baird DC">Baird DC, Batten SH, Sparks SK. Alpha- and Beta-thalassemia: Rapid Evidence Review. Am Fam Physician. 2022 Mar 1;105(3):272-280. PMID 35289581.</ref> The thalassemias are classified according to which chain of the hemoglobin molecule is affected. In α-thalassemias, production of the α-globin chain is affected, while in β-thalassemia, production of the β-globin chain is affected.<ref>Template:Cite journal</ref> <section end="Pathophys" />
Evolutionary advantageEdit
Having a mild form of alpha thalassemia has been demonstrated to protect against malaria and thus can be an advantage in malaria endemic areas, thus conferring a selective survival advantage on carriers (known as heterozygous advantage), and perpetuating the mutation.<ref name="Wambua-2006">Template:Cite journal</ref> There are suggestions that mild beta thalassemia may provide similar protection but this has not been proven.<ref>Template:Cite journal</ref><ref>Template:Cite journal</ref>
α thalassemia genes have a high prevalence in populations of sub-Saharan Africa, Mediterranean, Middle East, and southeast and east Asia. β-thalassemias are commonest in the populations of the Mediterranean, Middle East, and Southeast Asia.<ref>Template:Cite journal</ref><ref>Template:Cite journal</ref>
Alpha-thalassemiaEdit
{{#invoke:Labelled list hatnote|labelledList|Main article|Main articles|Main page|Main pages}} <section begin="alphathal" /> The α-globin chains are encoded by two closely linked genes HBA1<ref>{{#ifeq:|none||{{#switch: | short = OMIM: | shortlink = OMIM: | plain = Online Mendelian Inheritance in Man: | full | #default = Online Mendelian Inheritance in Man (OMIM):}}}} {{#if:Hemoglobin—Alpha locus 1; HBA1 |Hemoglobin—Alpha locus 1; HBA1 - }} 141800</ref> and HBA2<ref>{{#ifeq:|none||{{#switch: | short = OMIM: | shortlink = OMIM: | plain = Online Mendelian Inheritance in Man: | full | #default = Online Mendelian Inheritance in Man (OMIM):}}}} {{#if:Hemoglobin—Alpha locus 2; HBA2 |Hemoglobin—Alpha locus 2; HBA2 - }} 141850</ref> on chromosome 16; in a person with two copies on each chromosome, a total of four loci encode the α chain.<ref name="Robbins">Robbins Basic Pathology, Page No:428</ref> Two alleles are maternal and two alleles are paternal in origin. Alpha-thalassemias result in decreased alpha-globin production, resulting in an excess of β chains in adults and excess γ chains in fetus and newborns.
- In infants and adults, the excess β chains form unstable tetramers called hemoglobin H or HbH comprising 4 beta chains.
- In the fetus, the excess γ chains combine hemoglobin Bart's comprising 4 gamma chains
Both HbH and Hb Bart's have a strong affinity for oxygen but do not release it, causing oxygen starvation in the tissues. They can also precipitate within the RBC damaging its membrane and shortening the life of the cell.<ref name="Harewood-2023" />
The severity of the α-thalassemias is correlated with the number of affected α-globin alleles: the greater, the more severe will be the manifestations of the disease.<ref name="Galanello-2011">Template:Cite journal</ref><ref name="Alpha-NHS">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>
| # of faulty alleles | Types of alpha thalassemia<ref name="Galanello-2011"/><ref name="Alpha-NHS" /> | Symptoms |
|---|---|---|
| 1 | Silent carrier | No symptoms |
| 2 | Alpha thalassemia trait | Minor anemia |
| 3 | Hemoglobin H disease | Mild to moderate anemia; may lead normal life |
| 4 | Hemoglobin Bart’s hydrops fetalis | Death usually occurs in utero or at birth |
<section end="alphathal" />
Beta-thalassemiaEdit
{{#invoke:Labelled list hatnote|labelledList|Main article|Main articles|Main page|Main pages}} β-globin chains are encoded by the HBB gene on chromosome 11;<ref>{{#ifeq:|none||{{#switch: | short = OMIM: | shortlink = OMIM: | plain = Online Mendelian Inheritance in Man: | full | #default = Online Mendelian Inheritance in Man (OMIM):}}}} {{#if:Hemoglobin—Beta Locus; HBB |Hemoglobin—Beta Locus; HBB - }} 141900</ref> in a healthy person with two copies on each chromosome, two loci encode the β chain.<ref name="Robbins" /> In beta thalassemia, a single faulty gene can be either asymptomatic or cause mild disease; if both genes are faulty this causes moderate to severe disease.<ref name="Thein_2013">Template:Cite journal</ref>
Mutated alleles are called β+ when partial function is conserved and some beta-globin is generated, or βo when no functioning protein is produced.<ref name="Thein_2013" />
The situation of both alleles determines the clinical picture:<ref name="Shakeel-2023">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>
- β thalassemia major (Mediterranean anemia or Cooley anemia) is caused by a βo/βo genotype. No functional β chains are produced, and thus no hemoglobin A can be assembled. This is the most severe form of β-thalassemia.
- β thalassemia intermedia is caused by a β+/βo or β+/β+ genotype. In this form, some hemoglobin A is produced.
- β thalassemia minor is caused by a β/βo or β/β+ genotype. Only one of the two β globin alleles contains a mutation, so β chain production is not terribly compromised and patients may be relatively asymptomatic.<ref name="Shakeel-2023" />
Delta-thalassemiaEdit
{{#invoke:Labelled list hatnote|labelledList|Main article|Main articles|Main page|Main pages}} As well as alpha and beta chains present in hemoglobin, about 3% of adult hemoglobin is made of alpha and delta globin chains. Just as with beta thalassemia, mutations that affect the ability of this gene to produce delta chains can occur.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>
Combination hemoglobinopathiesEdit
A combination hemoglobinopathy occurs when someone inherits two different abnormal hemoglobin genes. If these are different versions of the same gene, one having been inherited from each parent it is an example of compound heterozygosity.
Both alpha- and beta- thalassemia can coexist with other hemoglobinopathies. Combinations involving alpha thalassemia are generally benign.<ref>Template:Cite journal</ref><ref>Template:Cite journal</ref>
Some examples of clinically significant combinations involving beta thalassemia include:
- Hemoglobin C/ beta thalassemia: common in Mediterranean and African populations generally results in a moderate form of anemia with splenomegaly.<ref>{{#invoke:citation/CS1|citation
|CitationClass=web }}</ref>
- Hemoglobin D/ beta thalassemia: common in the northwestern parts of India and Pakistan (Punjab region).<ref>Template:Cite journal</ref>
- Hemoglobin E/ beta thalassemia: common in Cambodia, Thailand, and parts of India, it is clinically similar to β thalassemia major or β thalassemia intermedia.<ref>Template:Cite journal</ref>
- Hemoglobin S/ beta thalassemia: common in African and Mediterranean populations, it is clinically similar to sickle-cell anemia.<ref name="Gerber-2024">{{#invoke:citation/CS1|citation
|CitationClass=web }}</ref>
- Delta-beta thalassemia is a rare form of thalassemia in which there is a reduced production of both the delta and beta globins. It is generally asymptomatic.<ref>Template:Cite book</ref>
DiagnosisEdit
<section begin="Thal_Diag" />
Prenatal and newborn screeningEdit
Checking for hemoglobinopathies begins during pregnancy, with a prenatal screening questionnaire which includes, among other things, a consideration of health issues in the child's parents and close relatives. During pregnancy, genetic testing can be done on samples taken of fetal blood, of amniotic fluid, or chorionic villus sampling.<ref name="Colah">Colah, R. B., Gorakshakar, A. C., & Nadkarni, A. H. (2011). Invasive & non-invasive approaches for prenatal diagnosis of haemoglobinopathies: experiences from India. The Indian Journal of Medical Research, 134(4), 552–560.</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> A routine heel prick test, in which a small sample of blood is collected a few days after birth, can detect some forms of hemoglobinopathy.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>
Diagnostic testsEdit
The initial tests for thalassemias are:
- Complete blood count (CBC): Checks the number, size, and maturity of blood cells. Hemoglobin of less than 10 g/dl may indicate a carrier, below 7 g/dl is indicative of thalassemia major. In thalassemia major, mean corpuscular volume (MCV) are less than 70 fl, in thalassemia intermedia, MCV levels are below 80 fl (The normal range for MCV is 80–100 fl).<ref name="Bajwa-2025">Template:Cite book</ref> The Mentzer index can be a pointer for diagnosis of thalassemia; it can can be calculated from a CBC report.<ref name="Kottke-2012">Template:Cite book</ref><ref name="Bajwa-2025" />
- Peripheral blood smear: A blood smear examined under a microscope can show red blood cells that are abnormal in shape (poikilocytosis or codocytes), color (hypochromic), or size (microcytic), as well as those with abnormal inclusions (Heinz bodies).<ref name="Bajwa-2025" />
- Serum iron and ferritin: these tests are needed to rule out iron-deficiency anemia.<ref name="Bajwa-2025" />
For an exact diagnosis, the following tests can be performed:
- Hemoglobin electrophoresis is a test that can detect different types of hemoglobin. Hemoglobin is extracted from the red cells, then introduced into a porous gel and subjected to an electrical field. This separates the normal and abnormal types of hemoglobin which can then be identified and quantified. Due to reduced production of HbA in beta thalassemia, the proportion of HbA2 and HbF relative to HbA are generally increased above normal. In alpha thalassemia the normal proportion is maintained.<ref>{{#invoke:citation/CS1|citation
|CitationClass=web }}</ref><ref name="Bajwa-2025" /><ref name="Harewood-2023">Template:Cite book</ref>
- High-performance liquid chromatography (HPLC) is reliable, fully automated, and able to distinguish most types of abnormal hemoglobin including carriers, The method separates and quantifies hemoglobin fractions by measuring their rate of flow through a column of absorbent material.<ref>Template:Cite journal</ref>
- DNA analysis using polymerase chain reaction (PCR) or next-generation sequencing. These tests can identify carriers of thalassemia genes and combination hemoglobinopathies, as well as identifying the exact mutation which underlies the disease.<ref name="Bajwa-2025" /><ref>Template:Cite journal</ref>
<section end="Thal_Diag" />
ManagementEdit
{{#invoke:Labelled list hatnote|labelledList|Main article|Main articles|Main page|Main pages}}<section begin="Thal_Management"></section>
Treatment for thalassemia depends on the severity of the disease. People with thalassemia traits (thalassemia minor or non transfusion dependent thalassemia), may not require medical or follow-up care after the initial diagnosis is made.<ref name="eMedicine_Pediatric"> Template:Emedicine</ref> Occasionally transfusions may be necessary particularly around childbirth, surgery, or if other conditions provoke anemia. A folic acid supplement may also be recommended.<ref name="Bajwa-2025" />
For those with severe forms of thalassemia (thalassemia major, or transfusion-dependent thalassemia), the three principal treatments are red blood cell transfusions to relieve anemia, iron chelation to mitigate the side effects of transfusion, and folic acid supplementation to encourage the growth of new blood cells.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> Other forms of treatment available depending on individual circumstances.
Red blood cell transfusionsEdit
Blood transfusions are the main treatment approach for prolonging life. Donated healthy red blood cells have a functional life of 4 to 6 weeks before they wear out and are broken down in the spleen. Regular transfusions every three to four weeks are necessary in order to maintain hemoglobin at a healthy level. Transfusions come with risks including iron overload, the risk of acquiring infections, and the risk of immune reaction to the donated cells (alloimmunization).<ref name="CDC-Treatment">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>
Iron chelationEdit
Multiple blood transfusions lead to severe iron overload, as the body eventually breaks down the hemoglobin in donated cells. This releases iron which it is unable to excrete. Iron overload may be treated by chelation therapy with the medications deferoxamine, deferiprone, or deferasirox.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> Deferoxamine is only effective as a daily injection, complicating its long-term use. Adverse effects include primary skin reactions around the injection site and hearing loss. Deferasirox and deferiprone are both oral medications, whose common side effects include nausea, vomiting and diarrhea.<ref>Template:Cite journal</ref>
Folic acidEdit
Folate is a B group vitamin which is involved in the manufacture of red blood cells. Folate supplementation, in the form of folic acid, is often recommended in thalassemia.<ref name="CDC-Treatment" />
Other treatmentsEdit
LuspaterceptEdit
Luspatercept is a drug used to treat anemia in adults with β-thalassemia, it can improve the maturation of red blood cells and reduce the need for frequent blood transfusions. It is administered by injection every three weeks. Luspatercept was authorised for use in the US in 2019 and by the European Medicines Agency in 2020.<ref>Template:Cite journal</ref>
HydroxyureaEdit
Hydroxyurea is another drug that can sometimes be administered to relieve anemia caused by beta-thalassemia. This is achieved, in part, by reactivating fetal haemoglobin production; however its effectiveness is uncertain.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>Template:Cite journal</ref><ref>Template:Cite journal</ref>
OsteoporosisEdit
People with thalassemia are at a higher risk of osteoporosis. Treatment options include bisphosphonates and zinc supplementation.<ref>Template:Cite journal</ref>
Removal of the spleenEdit
The spleen is the organ which removes damaged or misshapen red blood cells from the circulation. In thalassemia, this can lead to the spleen becoming enlarged, a condition known as splenomegaly. Slight enlargement of the spleen is not a problem, however if it becomes extreme then surgical removal of the spleen (splenectomy) may be recommended.<ref name="Mayo-2021" />
Transplantation and gene therapyEdit
Hematopoietic stem cells (HSC) are cells in the bone marrow that can develop into all types of blood cells, including red blood cells, white blood cells, and platelets.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> There are two possible ways to treat hemoglobinopathies by targeting HSCs. One is to transplant HSCs from a healthy donor into the patient's bone marrow; this was pioneered in 1981. More recently, it has become possible to use CRISPR gene editing technology to modify the patient's own HSCs in a way that increases production of functional beta-globin chains, leading to near normal levels of healthy hemoglobin.<ref>Template:Cite journal</ref>
All stem cell treatments must involve myeloablation of the patients' bone marrow in order to remove HSCs containing the faulty gene. This requires high doses of chemotherapy agents with side effects such as sickness and tiredness. A long hospital stay is necessary after infusion of the replacement HSCs while the cells take up residence in the bone marrow and start to make red blood cells with the stable form of haemoglobin.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref name="MHRA-2023" />
Hematopoietic stem cell transplantationEdit
Hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for both alpha and beta thalassemia. It involves replacing the dysfunctional stem cells in the bone marrow with healthy cells from a well-matched donor. Cells are ideally sourced from human leukocyte antigen matched relatives; the procedure is more likely to succeed in children rather than adults.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>Template:Cite journal</ref>
The first HSC transplant for thalassemia was carried out in 1981 on a patient with beta thalassemia major. Since then, a number of patients have received bone marrow transplants from healthy matched donors, although this procedure has a high level of risk.<ref>Template:Cite journal</ref>
In 2018 an unborn child with hydrops fetalis, a potentially fatal complication of alpha thalassemia, was successfully transfused in utero with her mother's stem cells.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>
HSCT is a dangerous procedure with many possible complications; it is reserved for patients with life-threatening diseases. Risks associated with HSCT can include graft-versus host disease, failure of the graft, and other toxicity related to the transplant.<ref name="Rotin-2023">Template:Cite journal</ref> In one study of 31 people, the procedure was successful for 22 whose hemoglobin levels improved to the normal range, in seven the graft failed and they continued to live with thalassemia, and two died of transplantation-related causes.<ref name="Sodani-2011">Template:Cite journal</ref>
Gene therapyEdit
Gene therapy for hemoglobinopathies was first trialled in 2014 on a single patient with sickle cell disease (a fault in the beta globin gene),<ref>Template:Cite journal</ref> and followed by clinical trials in which a number of patients with either sickle cell or beta thalassemia were successfully treated.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>
Gene therapies work by first harvesting the patient's HSCs, then using CRISPR gene editing to modify their DNA in the laboratory. In parallel with this, the person with thalassemia disease undergoes a myeloablation procedure (a form of chemotherapy) to destroy the remaining HSCs in their bone marrow. The laboratory treated cells are then infused back into the patient where they colonise the bone marrow and eventually commence production of healthy blood cells. There are fewer risks from this procedure than from HSCT, since the transplanted cells are autologous having originated from the patient herself/himself. <ref name="Biffi-2018">Template:Cite journal</ref>
There are two approved forms of gene therapy for beta thalassemia.<ref name="Zynteglo-2022">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>
Betibeglogene autotemcel, sold under the brand name Zynteglo, is a gene therapy for the treatment for beta thalassemia which adds a healthy beta-globin gene to the HSCs.<ref>Template:Cite journal</ref> It was approved for medical use in the United States in August 2022.<ref name="Zynteglo-2022" /><ref name="FDA Approves First Cell-2022">Template:Cite press release Template:PD-notice</ref> The procedure involves collecting hematopoietic stem cells (HSCs) from the affected person's blood. In the laboratory, these HSCs then have a new gene for T87Q-globin (a modified beta-globin) introduced to them using a lentiviral vector. Meanwhile the affected person undergoes myeloablative conditioning, after which the altered HSCs can be infused back, becoming engrafted in the bone marrow where they proliferate. This results in a progressive increase in beta-globin synthesis which improves the balance of alpha and beta globins in all subsequent developing red blood cells. Healthy hemoglobin A is generated resolving the anemia.<ref name="Biffi-2018" />
Exagamglogene autotemcel, sold under the brand name Casgevy, is a gene therapy for the treatment of transfusion-dependent beta thalassemia which induces increased production of fetal hemoglobin HbF.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> The treatment was approved in the United Kingdom for the treatment of transfusion-dependent beta thalassemia in November 2023<ref name="MHRA-2023">Template:Cite press release</ref> and in the United States in January 2024. Casgevy works by editing the BCL11A gene, which normally inhibits the production of HbF in adults. The edit has the effect of increasing production of gamma globin, a component of fetal hemoglobin HbF, and thereby resolving the anemia.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>
<section end="Thal_Management"></section>
PreventionEdit
The American College of Obstetricians and Gynecologists recommends all people thinking of becoming pregnant be tested to see if they have thalassemia.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> Genetic counseling and genetic testing are recommended for families who carry a thalassemia trait.<ref name="Hussein_2021">Template:Cite journal</ref> Understanding the genetic risk, ideally before a family is started, would hopefully allow families to understand more about the condition and make an informed decision that is best for their family.<ref name="Hussein_2021" />
A screening policy exists in Cyprus to reduce the rate of thalassemia, which, since the program's implementation in the 1970s (also including prenatal screening and abortion), has reduced the number of children born with the disease from one of every 158 births to almost zero.<ref>Template:Cite journal</ref> Greece also has a screening program to identify people who are carriers.<ref>Template:Cite journal</ref>
In Iran as a premarital screening, the man's red cell indices are checked first. If he has microcytosis (mean cell hemoglobin < 27 pg or mean red cell volume < 80 fl), the woman is tested. When both are microcytic, their hemoglobin A2 concentrations are measured. If both have a concentration above 3.5% (diagnostic of thalassemia trait) they are referred to the local designated health post for genetic counseling.<ref>Template:Cite journal</ref>
Large-scale awareness campaigns are being organized in India both by government and non-government organizations to promote voluntary premarital screening, with marriage between carriers strongly discouraged.<ref>Template:Cite journal</ref>
EpidemiologyEdit
The beta form of thalassemia is particularly prevalent among Mediterranean peoples, and this geographical association is responsible for its original name.<ref name="Greer2013_13"/> Thalassemias resulted in 25,000 deaths in 2013, down from 36,000 deaths in 1990.<ref name="Naghavi-2015">Template:Cite journal</ref>
In Europe, the highest concentrations of the disease are found in Greece, coastal regions in Turkey (particularly the Aegean Region such as İzmir, Balıkesir, Aydın, Muğla, and Mediterranean Region such as Antalya, Adana, Mersin), in southern Spain, in parts of Italy, particularly southern Italy. With the exception of the Balearics, the major Mediterranean Islands, such as Sicily, Sardinia, Malta, Corsica, Cyprus, and Crete are heavily affected. Other Mediterranean peoples, as well as those in the vicinity of the Mediterranean, also have high rates of thalassemia, including people from North Africa and West Asia. Far from the Mediterranean, South Asians are also affected, with the world's highest concentration of carriers (16–18% of the population) in the Maldives.<ref>Template:Cite journal</ref>
The disease is also found in populations living in Africa, the Americas, and in Tharu people in the Terai region of Nepal and India.<ref>Template:Cite journal</ref> It is believed to account for much lower rates of malaria illnesses and deaths,<ref>Template:Cite journal</ref> accounting for the historic ability of Tharus to survive in areas with heavy malaria infestation while others could not. Thalassemias are particularly associated with people of Mediterranean origin, Arabs (especially Palestinians and people of Palestinian descent), and Asians.<ref>E. Goljan, Pathology, 2nd ed. Mosby Elsevier, Rapid Review Series.Template:Page needed</ref> The estimated prevalence is 16% in people from Cyprus, 1%<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> in Thailand, and 3–8% in populations from Bangladesh, China, India, Malaysia and Pakistan.
Estimates suggest that approximately 1.5% of the global population (80 – 90 million people) are β-thalassemia carriers.<ref name="Galanello-2010">Template:Cite journal</ref> However, exact data on carrier rates in many populations are lacking, particularly in developing areas of the world known or expected to be heavily affected.<ref name="Galanello-2010" /><ref>Template:Cite journal</ref> Because of the prevalence of the disease in countries with little knowledge of thalassemia, access to proper treatment and diagnosis can be difficult.<ref name="Weatherall-2005">Template:Cite journal</ref> While there are some diagnostic and treatment facilities in developing countries, in most cases these are not provided by government services and are available only to patients who can afford them. In general, poorer populations only have access to limited diagnostic facilities and blood transfusions. In some developing countries, there are virtually no facilities for diagnosis or management of thalassemia.<ref name="Weatherall-2005"/>
History of thalassemiaEdit
Rudolf Von Jaksch in 1889 first described “anaemia leucaemic infantum” as a form of chronic anemia in children which combined with an enlarged spleen, and abnormal size and shape of the red blood cells. His discovery was subsequently found to comprise a collection of different conditions.<ref name=":0">Template:Cite journal</ref>
The first definitive identification of a thalassemia was in 1925 by Thomas Benton Cooley, an American pediatrician specialising in hematology and childhood anemias. Cooley noted similarities in symptoms of children in his care having Greek or Italian ancestry; he named it "erythroblastic anemia," but it became popularly known as Cooley's anemia (now termed beta thalassemia major).<ref>Template:Cite book</ref>
The term "thalassemia" was coined by George Whipple in 1932. The word "thalassemia" comes from the Greek word thalassa, which means "sea". The suffix "-emia" comes from the Greek word haima, which means "blood". The term was coined because the condition was strongly associated with people of Mediterranean descent.<ref name=":0" />
In 1948, Italian researchers established that the type of thalassemia which was prevalent in Italy was inherited in a recessive pattern.<ref>Template:Cite journal</ref><ref>Template:Cite journal</ref>
ResearchEdit
Further readingEdit
ReferencesEdit
External linksEdit
- {{#invoke:citation/CS1|citation
|CitationClass=web }}